HIF1A and the Biology of Progression in Multiple Sclerosis
A recent study in Acta Neuropathologica investigates one of the central unresolved questions in multiple sclerosis (MS): why some patients accumulate severe disability over time, whereas others remain comparatively stable for decades. The authors focused on “smoldering inflammation,” a chronic, compartmentalized inflammatory process that persists at the edges of long-standing lesions and is increasingly recognized as a major driver of progressive tissue damage in MS. Using a discovery-and-replication design across Italian and Swedish cohorts totaling 2,817 patients, the study identifies a variant in the HIF1A gene that is associated with a more favorable long-term disease course. Specifically, carriers of the protective allele were more likely to remain free of substantial disability progression more than 20 years after disease onset.
Why Smoldering Inflammation Matters in MS
The importance of this work lies in its focus on progression rather than relapse alone. In MS, inflammatory relapses and new MRI lesions explain only part of the disease burden. Many patients later enter a phase in which disability worsens gradually even without overt relapses, and current therapies often have limited effectiveness against this process. The article argues that smoldering inflammation, especially around chronic active lesions enriched in iron and activated myeloid cells, represents a key pathological substrate of this slow decline. To interrogate this biology, the investigators selected 334 genes related to iron metabolism and analyzed more than 23,000 genetic variants within them, reasoning that iron handling is deeply linked to the chronic inflammatory lesion environment. This candidate-pathway strategy led them to a locus on chromosome 14 assigned to HIF1A, a master regulator of cellular responses to hypoxia.
The Protective HIF1A Variant and Long-Term Clinical Outcome
The lead signal was the variant rs11621525, whose minor A allele was associated with higher odds of a favorable disease course in the Italian discovery cohort, and this association was independently replicated in the Swedish cohort through a closely linked proxy variant. The clinical contrast used in the study was stringent and clinically meaningful: patients with relapsing-remitting MS who remained at low disability after more than 20 years from onset were compared with patients who converted to secondary progressive MS within 20 years and had accumulated greater disability. This design strengthens the biological relevance of the finding because it compares phenotypic extremes of long-term outcome. The authors further linked the variant to HIF1A through functional prioritization tools and expression quantitative trait locus evidence, including confirmation in peripheral blood mononuclear cells from treatment-naive MS patients, supporting the idea that the association is not merely positional but mechanistically plausible.
MRI and Neurofilament Evidence for Reduced Ongoing Tissue Damage
One of the strongest features of the paper is that it does not stop at genetic association. The authors examined whether the protective allele also corresponded to measurable reductions in biological markers of chronic injury. On MRI, carriers of the protective allele showed lower paramagnetic rim lesion volume. These lesions, illustrated in the workflow on page 6, are increasingly regarded as imaging signatures of chronic active inflammation driven by iron-laden microglia and macrophages at lesion edges. In parallel, the study found lower levels of neurofilament light chain in both plasma and cerebrospinal fluid among carriers of the protective allele, indicating reduced axonal injury. Taken together, these findings suggest that the HIF1A-associated signal is not simply correlated with disability in an abstract statistical sense, but is also reflected in less active chronic lesion pathology and lower neuroaxonal damage in vivo.
Post-Mortem Pathology Connects the Variant to Lesion Biology
The neuropathological analyses add another important layer of evidence. In post-mortem spinal cord tissue from progressive MS cases, individuals carrying the protective allele showed reduced CD68-positive microglia/macrophage inflammation and less acute axonal injury, particularly in mixed active/inactive lesions, which are thought to correspond to the chronic active lesion state. The study also reports lower iron concentration in chronic active spinal cord lesions among protective allele carriers, along with a striking reduction in cortical iron rim-positive lesions in the brain. Even non-lesional white matter outside plaques showed evidence of less injury in carriers of the protective genotype. These observations reinforce the central interpretation of the paper: the HIF1A variant appears to modulate the inflammatory-metabolic environment that sustains chronic lesion expansion and diffuse tissue damage in progressive MS.
Single-Cell and Spatial Transcriptomic Insights into Mechanism
The mechanistic dimension of the article becomes especially compelling in its integration of single-nucleus RNA sequencing and spatial transcriptomics. The authors demonstrate that the effect of the variant on HIF1A expression is cell-type specific and context dependent. In several cell populations within chronic active tissue, the protective allele was associated with increased HIF1A expression, yet in one immune-cell subcluster identified as monocyte-derived dendritic cells exposed to hypoxic conditions, the same allele was associated with reduced HIF1A expression. This inverse effect was specific to the chronic active lesion environment and was not seen in chronic inactive lesions or periplaque white matter. Spatial transcriptomics then localized a closely matching phagocytic myeloid population to the lesion rim and core, as shown in the figures on pages 12 and 13. This supports the idea that the protective genetic effect may operate through a specialized myeloid state positioned precisely where smoldering inflammation is most damaging.
Scientific and Therapeutic Implications
This study is important because it moves from gene discovery to biological interpretation with unusual depth. It implicates HIF1A, a central regulator of hypoxia-responsive transcription, in the chronic inflammatory ecology of MS lesions and suggests that inherited variation can influence how strongly that ecology drives tissue injury and disability. The work also fits into a broader conceptual framework in which “virtual hypoxia,” mitochondrial stress, iron dysregulation, and innate immune activation converge in progressive neuroinflammatory disease. Although the study does not establish causality and still requires functional validation in experimental systems, it identifies a credible molecular pathway that may be therapeutically actionable. For the field of MS research, the message is clear: progression may be shaped not only by immune activation in general, but by genetically modulated responses to hypoxic and iron-rich lesion microenvironments. That insight may help guide future strategies aimed at slowing disability accumulation, a goal that remains one of the most urgent unmet needs in MS care.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Giordano, A., Stridh, P., Preziosa, P. et al. A HIF1A variant impacts long-term disability and smoldering inflammation in multiple sclerosis. Acta Neuropathol 151, 12 (2026). https://doi.org/10.1007/s00401-026-02984-w
